Interferon beta 1 (beta 1b), Recombinant, Human (IFNb1, IFNb1b)

Recombinant protein corresponding to 165aa of human Interferon-beta 1b expressed in E.coli is a single, non-glycosylated mutein (variant form) of human Interferon beta-1b polypeptide chain.\n\nBiological Activity:\nThe specific activity as determined in a viral resistance assay (human "Wish" cell line and VSV virus or the monkey VERO cell line with EMCV virus) was found to be 32x10^6 IU/mg.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.493 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of IFN-beta as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, 0.1% HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I7662-14T

Size

10ug

Form

Supplied as a lyophilized powder from a solution containing 50mg human albumin and 50mg dextrose. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug

References

1. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005 Dec;11(6):658-68. 2. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. J Neurol 2005 Sep;252 Suppl 3:iii28-iii33. 3. 10 years of interferon beta-1b (Beta feron therapy. J Neurol 2005 Sep;252 Suppl 3:iii1-iii2. 4. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005 Nov;62(11):1684-8. 5. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b. Australas J Dermatol 2005 Aug;46(3):202-4. 6. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol 2005 Aug;46(3):154-7.